MTOR and breast cancer: We observed a difference in the ATP levels between STK11−/−/NIC mammary tumors and WT mammary tissue, reflective of the loss of LKB1 expression and therefore regulation of AMPK activity, leading to hyperactivation of mTOR through both mTORC1 and mTORC2 pathways.